{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:06:16Z","timestamp":1787241976265,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/bjc.2017.371","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T16:00:56Z","timestamp":1510675256000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders"],"prefix":"10.1038","volume":"118","author":[{"given":"J U H","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K M","family":"Elfstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Ejegod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rebolj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lynge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K E","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"issue":"7","key":"BFbjc2017371_CR1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ijc.22484","volume":"120","author":"AG Bais","year":"2007","unstructured":"Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, Babovic M, van Ballegooijen M, Helmerhorst TJ, Meijer CJ (2007) Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 120 (7): 1505\u20131510.","journal-title":"Int J Cancer"},{"issue":"7 Suppl","key":"BFbjc2017371_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1403494810393563","volume":"39","author":"B Bjerregaard","year":"2011","unstructured":"Bjerregaard B, Larsen OB (2011) The Danish Pathology Register. Scand J Public Health 39 (7 Suppl): 72\u201374.","journal-title":"Scand J Public Health"},{"key":"BFbjc2017371_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/1471-2334-14-413","volume":"14","author":"J Bonde","year":"2014","unstructured":"Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C (2014) HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system. BMC Infect Dis 14: 413.","journal-title":"BMC Infect Dis"},{"key":"BFbjc2017371_CR4","unstructured":"(2014) Danish Quality Assurance Database for the Cervical Cancer Screening Program Annual report 2014 Vol. 2015."},{"issue":"3-4","key":"BFbjc2017371_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ypmed.2012.01.012","volume":"54","author":"PA Dugue","year":"2012","unstructured":"Dugue PA, Lynge E, Bjerregaard B, Rebolj M (2012) Non-participation in screening: the case of cervical cancer in Denmark. Prev Med 54 (3-4): 266\u2013269.","journal-title":"Prev Med"},{"key":"BFbjc2017371_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12885-015-1223-z","volume":"15","author":"DM Ejegod","year":"2015","unstructured":"Ejegod DM, Rebolj M, Bonde J (2015) Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study. BMC Cancer 15: 216.","journal-title":"BMC Cancer"},{"issue":"4","key":"BFbjc2017371_CR7","doi-asserted-by":"publisher","first-page":"e0151978","DOI":"10.1371\/journal.pone.0151978","volume":"11","author":"E Enerly","year":"2016","unstructured":"Enerly E, Bonde J, Schee K, Pedersen H, Lonnberg S, Nygard M (2016) Self-sampling for human Papillomavirus testing among non-attenders increases attendance to the Norwegian cervical cancer screening programme. PLoS One 11 (4): e0151978.","journal-title":"PLoS One"},{"key":"BFbjc2017371_CR8","doi-asserted-by":"publisher","first-page":"c1040","DOI":"10.1136\/bmj.c1040","volume":"340","author":"M Gok","year":"2010","unstructured":"Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, Voorhorst F, Belien JA, Babovic M, Snijders PJ, Meijer CJ (2010) HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340: c1040.","journal-title":"BMJ"},{"issue":"12","key":"BFbjc2017371_CR9","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.ejca.2011.11.022","volume":"48","author":"M Gok","year":"2012","unstructured":"Gok M, Heideman DA, van Kemenade FJ, de Vries AL, Berkhof J, Rozendaal L, Belien JA, Overbeek L, Babovic M, Snijders PJ, Meijer CJ (2012) Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders. Eur J Cancer 48 (12): 1799\u20131808.","journal-title":"Eur J Cancer"},{"issue":"10","key":"BFbjc2017371_CR10","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1128\/JCM.00550-17","volume":"55","author":"JU Lam","year":"2017","unstructured":"Lam JU, Rebolj M, Ejegod DM, Pedersen H, Rygaard C, Lynge E, Thomsen LT, Kjaer SK, Bonde J (2017) Prevalence of human papillomavirus in self-taken samples from screening nanottenders. J Clin Microbiol 55 (10): 2913\u20132923.","journal-title":"J Clin Microbiol"},{"key":"BFbjc2017371_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-016-2518-4","volume":"16","author":"S Preisler","year":"2016","unstructured":"Preisler S, Rebolj M, Ejegod DM, Lynge E, Rygaard C, Bonde J (2016) Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study. BMC Cancer 16: 510.","journal-title":"BMC Cancer"},{"issue":"3","key":"BFbjc2017371_CR12","doi-asserted-by":"publisher","first-page":"e59765","DOI":"10.1371\/journal.pone.0059765","volume":"8","author":"S Preisler","year":"2013","unstructured":"Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, Bonde J (2013) Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PLoS One 8 (3): e59765.","journal-title":"PLoS One"},{"issue":"11","key":"BFbjc2017371_CR13","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.ejca.2015.04.012","volume":"51","author":"M Rebolj","year":"2015","unstructured":"Rebolj M, Bonde J, Ejegod D, Preisler S, Rygaard C, Lynge E (2015a) A daunting challenge: human papillomavirus assays and cytology in primary cervical screening of women below age 30years. Eur J Cancer 51 (11): 1456\u20131466.","journal-title":"Eur J Cancer"},{"issue":"11","key":"BFbjc2017371_CR14","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1128\/JCM.01321-16","volume":"54","author":"M Rebolj","year":"2016","unstructured":"Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E (2016a) Differential detection of human papillomavirus genotypes and cervical intraepithelial neoplasia by four commercial assays. J Clin Microbiol 54 (11): 2669\u20132675.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"BFbjc2017371_CR15","doi-asserted-by":"publisher","first-page":"e0147326","DOI":"10.1371\/journal.pone.0147326","volume":"11","author":"M Rebolj","year":"2016","unstructured":"Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E (2016b) Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above. PLoS One 11 (1): e0147326.","journal-title":"PLoS One"},{"issue":"3","key":"BFbjc2017371_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ygyno.2014.10.014","volume":"135","author":"M Rebolj","year":"2014","unstructured":"Rebolj M, Lynge E, Ejegod D, Preisler S, Rygaard C, Bonde J (2014a) Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology. Gynecol Oncol 135 (3): 474\u2013480.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"BFbjc2017371_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jmoldx.2013.04.002","volume":"15","author":"M Rebolj","year":"2013","unstructured":"Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E (2013) Prevalence of human papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay. J Mol Diag 15 (5): 670\u2013677.","journal-title":"J Mol Diag"},{"issue":"1","key":"BFbjc2017371_CR18","doi-asserted-by":"publisher","first-page":"e86835","DOI":"10.1371\/journal.pone.0086835","volume":"9","author":"M Rebolj","year":"2014","unstructured":"Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J (2014b) Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. PLoS One 9 (1): e86835.","journal-title":"PLoS One"},{"issue":"9","key":"BFbjc2017371_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/bjc.2015.339","volume":"113","author":"M Rebolj","year":"2015","unstructured":"Rebolj M, Rask J, van Ballegooijen M, Kirschner B, Rozemeijer K, Bonde J, Rygaard C, Lynge E (2015b) Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark. Br J Cancer 113 (9): 1259\u20131274.","journal-title":"Br J Cancer"},{"issue":"5","key":"BFbjc2017371_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1158\/1055-9965.EPI-14-0998","volume":"24","author":"K Rozemeijer","year":"2015","unstructured":"Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, van Ballegooijen M (2015) Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits? Cancer Epidemiol Biomarkers Prev 24 (5): 773\u2013782.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"BFbjc2017371_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.30031","volume":"139","author":"F Sultana","year":"2016","unstructured":"Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, Wrede CD, Heley S, Saville M, Gertig DM (2016) Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia. Int J Cancer 139 (2): 281\u2013290.","journal-title":"Int J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017371","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:40:07Z","timestamp":1684402807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFbjc2017371"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.371","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]},"assertion":[{"value":"10 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JUHL attended meetings with various HPV device manufacturers. MR attended meetings with various HPV device manufacturers. She and her former employer received fees for lectures on her behalf from Qiagen. DME attended meetings with various HPV device manufacturers. She received honoraria from BD and Qiagen for lectures. HP attended meetings with various HPV device manufacturers. CR participated in meetings with Roche with fee paid to the University of Copenhagen. EL participated in meetings with Roche and Astra-Zeneca with fees paid to the University of Copenhagen, and was unpaid advisor to GenProbe and NorChip. Roche has provided test kits to Trial23. SKK has received lecture fees, scientific advisory board fees from Merck, Sanofi Pasteur MSD, BD, and unrestricted research grants through the affiliating institute from Merck. JD has received grants to his institution for studies on HPV vaccination from Merck\/SPMSD. JB attended meetings with various HPV device manufacturers. He used to serve as a paid advisor to Roche and Genomica, and has received honoraria from Hologic\/Gen-Probe, Roche, Qiagen, Genomica, and BD Diagnostics for lectures. He is principal investigator on studies funded by BD diagnostics. Hvidovre Hospital holds a recompense agreement with Genomica on a KRAS\/BRAF diagnostic system. KME and KEJ declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}